GlassScriptPhysician profile
Kathryn T Keyzer
NPI 1881697217
$4,340.30
in general payments reported to CMS, 2019-2025
14 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2021: $289 · 2022: $1,159 · 2023: $877 · 2024: $504 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587 · Consulting Fee: $600 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.39 |
| Consulting Fee | $600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,350.17 | 2021-2025 | Clariti Contact Lens, Paragon Crt |
| Johnson & Johnson Vision Care, INC. | $710.04 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $555.50 | 2019-2025 | Air Optix |
| Bausch & Lomb Americas INC. | $388.06 | 2023-2025 | Vyzulta, Lotemax Sm, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $307.81 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $263.88 | 2024-2025 | Xdemvy |
| Visionary Optics LLC | $150.51 | 2023 | |
| Lumenis Be INC | $149.78 | 2023 | Optilight |
| Alexion Pharmaceuticals, INC. | $121.86 | 2025 | Ultomiris |
| Astellas Pharma US INC | $121.86 | 2025 | Izervay |
| Emd Serono, INC. | $101.97 | 2019 | |
| Glaukos Corporation | $64.28 | 2023 | |
| Dompe US, INC. | $32.84 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $21.74 | 2023 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Keyzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.